ASCO22 Highlights from Day 1
After weeks of waiting ASCO has finally arrived!
There are a surprising number of intriguing presentations at this meeting for those prepared to hunt off the radar, with some interesting implications to be considered in a broader context.
There were several to be found even on the very first day of action – they don’t all have to be massive phase 3 studies to make an impact.
Here we look at some of the highlights we heard about in between doing expert interviews for colour commentary and context. One such example is included here where it turned out there were some strategic commercial considerations involved as well…
To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers